Founded in 2009, JYMed is a leading peptide CRDMO service provider and generic API manufacturer in China specializing in the custom synthesis, process development, clinical supply and commercialization of peptide substances. The company employs approximately 600+ FTEs, with a core management team composed of experts with over 20 years of experience in peptide technology. JYMed operates one R&D center and two major multi-purpose production facilities, with multi-ton scale peptide manufacturing capacity.
As a customer-focused company, JYMed offers a comprehensive peptide development and industrialization platform backed by over 20 years of R&D expertise and state-of-the-art facilities. We deliver high-quality peptides tailored to each client’s needs.
JYMed provides a broad portfolio of over 20 peptide APIs, including Semaglutide, Tirzepatide, Liraglutide, Degarelix, and Oxytocin. Several of these, such as Semaglutide and Tirzepatide, have successfully completed registration and commercialization.
JYMed offers a comprehensive and efficient CDMO platform, providing full-spectrum services for peptide and peptide-analog products. This includes the research and production of therapeutic peptides, veterinary peptides, and more.
JYMed supplies high-quality cosmetic peptides, raw materials, and OEM formulations ranging from research to cGMP grade—all under strict quality control. Our synthetic peptides are widely valued for their safety, purity, and ease of customization.
JYMed is a US FDA-inspected peptide manufacturer specializing in cosmetic peptides, peptide APIs, and custom peptides. Our featured products include Semaglutide, Liraglutide, Tirzepatide, Oxytocin, GHK, GHK-Cu, Acetyl Hexapeptide-8, and more. To learn more, please contact us at:
Email: jymed@jymedtech.com
CPHI China 2025 will take place from June 24–26, 2025, at the Shanghai New International Expo Centre (SNIEC). Spanning more than 230,000 square meters, the event is set to host over 3,500 exhibitors and attract more than 100,000 industry professionals. As one of Asia’s largest and most influenti...
Hubei JXBio Pharmaceutical Co., Ltd., JYMed’s dedicated peptide production site, successfully completed another on-site inspection by the U.S. Food and Drug Administration (FDA) from March 10-14. The inspection, part of a Drug Quality Assurance audit, evaluated key systems including quality, prod...
JYMed has implemented a robust quality management system, earning three certifications for consistently delivering products and services that meet global standards.The achievement of ISO 9001 certification demonstrates that the company has well-defined processes and standards for internal managem...